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Introduction
icture the world in 2050. A demographic shift
towards older age that began generations ago will have
reached its peak, and 2 billion individuals will be aged 60
and older.
1 In the United States and much of Europe,
one in three persons will be in this old-age demographic
(compared with one in five today). It is increasingly clear
that the common mental disorders of emotion— anxiety
disorders and unipolar depression—are a terrible
scourge across the lifespan: they not only induce signifi-
cant misery and suffering for the patient and his/her
whole family, but with increasing age they become
increasingly deleterious to health and cognition, even
increasing mortality risk in older adults. Given such dele-
terious effects, understanding the common mental dis-
orders in this large and growing demographic would
seem to be a question of some importance. 
The last decade has seen several advances in our knowl-
edge of the epidemiology, course, and treatment of anx-
iety disorders, and how this changes into old age. Yet,
even though anxiety disorders are the most common
mental disorders in older adults, there has been scant
attention paid to some major issues regarding anxiety
disorders in older adults. 
In this review, we present a lifespan view of anxiety dis-
orders, primarily from an aging perspective, but also with
an examination of the changing picture of anxiety dis-
orders and their treatment throughout the lifespan from
childhood to old age. This review will focus on three
aspects of anxiety disorders: epidemiology, presentation,
and treatment. One of the major arguments that will be
advanced is that anxiety disorders are common in older
adults and cause considerable distress and functional
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Neurodevelopmental changes over the lifespan, from
childhood through adulthood into old age, have impor-
tant implications for the onset, presentation, course, and
treatment of anxiety disorders. This article presents data
on anxiety disorders as they appear in older adults, as
compared with earlier in life. In this article, we focus on
aging-related changes in the epidemiology, presentation,
and treatment of anxiety disorders. Also, this article
describes some of the gaps and limitations in our under-
standing and suggests research directions that may eluci-
date the mechanisms of anxiety disorder development
later in life. Finally, we describe optimal management of
anxiety disorders across the lifespan, in “eight simple
steps” for practitioners.   
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impairment, and that, absent improvements in detection
and management, geriatric anxiety disorders will
become an increasing human and economic burden. We
will also argue that much is known already about the
optimal management of anxiety disorders across the
lifespan into old age, such that practitioners could
greatly improve outcomes of their patients with these
common problems even now, if they follow eight simple
management steps which are outlined.
Additionally, it will be obvious from reading this review
that significant gaps remain in our understanding of
many aspects of anxiety disorders, particularly in older
adults. Throughout the review, we will point out these
gaps in our knowledge, and we will finish with a brief
prospectus on research that could begin to fill these gaps.
Epidemiology of anxiety disorders 
throughout the lifespan
Table I shows prevalence estimates from several large
epidemiologic studies that focused on elderly persons.
As a whole, the studies suggest that generalized anxiety
disorder (GAD) is the most common anxiety disorder
and is as common, or more common, in older as in
younger adults; other anxiety disorders are less common. 
Several excellent reviews of the epidemiology of late-life
anxiety disorders exist
2-4 and we will not recapitulate
them, but will note two key and related points from
them. First, epidemiologic studies have produced wide
variations in prevalence estimates of anxiety disorders
in elderly persons. One systematic review found 28 epi-
demiological studies of anxiety symptoms, or disorders,
in older adults: 19 in community samples, and nine in
clinical samples. The range of anxiety disorder preva-
lence estimates in those studies varied markedly, rang-
ing from 1.2% to 15% in community samples and from
1% to 28% in medical settings. The prevalence of clini-
cally significant anxiety symptoms ranges from 15% to
52% in community samples and 15% to 56% in medical
settings.
2 Second, anxiety disorders (and symptoms),
already difficult to measure accurately in young adults,
are more difficult to assess in older adults. In a section
below, we will discuss difficulties in the assessment and
diagnosis of anxiety disorders and symptoms in older
adults and how these might affect prevalence estimates.
Presentation of anxiety disorders 
across the lifespan
Figure 1 portrays our current understanding of how dif-
ferent forms of anxiety disorders may predominate at
different stages of the lifespan. Phobias (particularly
social and specific phobias) may predominate in child-
hood; panic disorder and post-traumatic stress disorder
(PTSD) may be at their highest prevalence in adulthood;
while worry disorders (ie, GAD) may be most common
in old age. Anxiety disorders with a strong autonomic
nervous system component (eg, resulting in panic attacks
or panic-like symptoms) are usually considered to be
more common in childhood or early adulthood than
Longitudinal Epidemiologic Amsterdam  Australian  National Canadian National
Aging Study  Catchment  Study of the  Mental Health and Community Health  Comorbidity
Amsterdam Area Elderly Well-being Study Survey (CCHS)
229 Study-Replication
(LASA)
11 (ECA)
227 (AMSTEL)
26 (NMHWS)
228 (NCS-R)
230
N 3107 5702 4051 1792 12792 1461
Age 55-85 65+ 65-84 65+ 55+ 65+
Any anxiety disorder 10.2% 5.5% Not assessed 4.4% Not assessed 7.0%
GAD 7.3% 1.9%* 3.2% 2.4% Not assessed 1.2%
Any phobia 3.1% 4.8% Not assessed Not assessed Not assessed 4.7%***
Social phobia Not assessed Not assessed Not assessed 0.6% 1.3% 2.3%
Agoraphobia Not assessed Not assessed Not assessed 0.8%** 0.6% 0.4%
Panic disorder 1.0% 0.1% Not assessed 0.8%** 0.8% 0.7%
OCD 0.6% 0.8% Not assessed 0.1% Not assessed Not assessed
PTSD 0.9% Not assessed Not assessed 1.0% Not assessed 0.4%
Table I. Prevalence estimates for anxiety disorders in older adults from five community studies. GAD, generalized anxiety disorder; OCD, obsessive-
compulsive disorder; PTSD, post-traumatic stress disorder; *prevalence estimate of GAD in ECA is from one site only; **prevalence estimate
from NMHWS is for panic disorder and/or agoraphobia ; ***prevalence estimate from NCS-R is for specific phobia
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later in life, particularly with respect to social phobia and
panic disorder. Age-related changes in brain structure or
function or peripheral physiology likely reduce the
propensity for autonomic responses.
5 Here we note the
caveat that specific disorders “may” peak at different
times in the lifespan because these data are largely based
on epidemiological studies. The difficulty of retrospec-
tive evaluation of age of onset of mental disorders is a
limitation to this assertion,
6 as is the difficulty of detect-
ing late-onset anxiety disorders using standardized
assessment tools that were developed for young adults..
2
Additionally, fear of falling (FOF) is a common and
uniquely geriatric syndrome
7 marked by fear and avoid-
ance. High rates of older adults in the community report
a FOF,
8 and in its more severe forms the consequences
of this fear are very serious, including a curtailing of
activities
9; thus the problem is akin to agoraphobia in the
more severe manifestation. However, it appears difficult
to diagnose FOF as an anxiety disorder, due in large part
to issues with insight and goodness of fit with existing
DSM-IV nosology.
10The one anxiety disorder that seems
to be more commonly present in late life is GAD.
11
Why might anxiety disorders 
develop late in life?
Although anxiety disorders are properly thought of as
neurodevelopmental conditions (ie, they develop in the
context of brain changes which occur characteristically at
various points in the lifespan), this does not mean that
they are of childhood onset only. In fact, anxiety can
develop in old age: one study found new-onset anxiety
disorders in 11% of older women and 2% of older men.
12
Up to one half of older patients with GAD have onset
later in life.
13-15 A review of European epidemiological
studies found that the incidence of agoraphobia may
increase over the lifespan in women.
16While older adults
may develop PTSD less frequently after traumatic events
than younger adults do,
17 late-onset PTSD is not uncom-
mon.
18-20 Even panic disorder, thought to have a particu-
larly low late-life incidence, has been documented in some
studies,
21 particularly in patients with medical illness.
22
There are potential neurobiological risks for late-onset
anxiety disorders (although these have not been sub-
jected to empirical testing). We conceptualize patholog-
ical anxiety as potentially due to a functional disconnect
between amygdala (and possibly insula) and frontal
areas (including anterior cingulate cortex, dorsolateral
and ventromedial prefrontal cortex), impairing natural
fear extinction and thus converting fears or worries into
chronic pathological conditions.
23 This process could be
exaggerated in elderly persons, in whom aging and neu-
rodegenerative changes may lead to reduced functional
connectivity.
24,25 Late-onset anxiety may thus be concep-
tualized as a consequence of neurobiological changes in
aging involving pathways which are suspects in the onset
and chronicity of anxiety disorders. 
Psychological and social risk factors also play a role in
the development of late-onset anxiety disorders. Some
risk factors for geriatric anxiety and depression are
shared, eg, female gender, cognitive impairment, chronic
health conditions, poor self-rated health, functional lim-
itations, personality traits such as neuroticism, and poor
coping skills.
26,27Additional risk factors for anxiety specif-
ically are being childless, having lower income, and expe-
riencing traumatic events. 
These psychosocial and neurobiological changes in aging
interact with each other and with predisposition (eg,
genetic or early-life adversity) to produce late-onset anx-
iety disorders. Additionally, age-related protective fac-
tors may include social support, religiosity, physical activ-
ity, cognitive stimulation, and effective coping skills
learned throughout a lifetime. As in childhood disorders,
such protective factors may buffer the effects of genetic
and other risk factors. 
Prospective studies are needed to study these risk and
protective factors and their interactions. One option is
to conduct a preventive intervention study for late-life
anxiety disorders.
28 A preventive intervention study
could enroll subjects with one or more of these risk fac-
tors, probably those with subsyndromal depressive or
Figure 1. Changes in anxiety disorder presentation across the lifespan.
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anxiety symptoms, and manage them with a stepped-
care approach to prevent the onset of an anxiety disor-
der.
29 Such a preventive study could gather biological
and behavioral data to elucidate biological, psychologi-
cal, and social variables associated with increased likeli-
hood of developing chronic anxiety. Elucidation of such
risk signatures could then lead to a second generation of
more robust preventive interventions that could target
individuals most likely to benefit from prevention and
intervene directly on the modifiable risk.
30 Such research
would be consistent with the National Institute of
Mental Health’s vision of “pre-emptive” and “personal-
ized” mechanistic-based novel intervention develop-
ment.
31
Course
Anxiety disorders are among the most persistent men-
tal health syndromes. The few longitudinal studies that
have been carried out in older adults with anxiety sug-
gest that they tend to be persistent in this age group.
32
Anxious older adults in epidemiological and treatment-
seeking samples retrospectively report an average dura-
tion of 20 years or more, at least in the case of
GAD.
13,14,33,34
Anxiety’s association with disability is greater with
increasing age and it is bidirectional.
35Anxiety increases
disability
36 and appears in some studies to be associated
with increased mortality risk.
37-40Additionally, significant
quality of life impairment and increased burden of
health care cost has been noted in GAD in older adults,
on a par with that seen in late-life depression.
41,42
Perhaps more uniquely in older adults, data suggest that
chronic pathological anxiety is toxic to brain health.
Anxiety symptoms or disorders in elderly are associated
with accelerated cognitive decline.
43-45 Below are some
putative mechanisms based on an examination of recent
mechanistic research.
Chronic psychological distress in older adults results in
impairments in cognition
46-49 and it is thought that a key
mechanism for this relationship involves changes in the
hypothalamic-pituitary-adrenal (HPA) axis.
50 The HPA
axis is a neuroendocrine mediator of stress and its cen-
tral nervous system (CNS) effects (Figure 2). 
The aging brain is less able to downregulate the HPA
axis
51-56 and is more vulnerable to physiological insults.
57,58
As a result, in older adults, chronic anxiety can cause
HPA axis hyperactivity,
59-64 with deleterious effects on
memory and executive function.
48,53,61,65-75 The putative
mechanism is an effect of high cortisol on brain struc-
tures (eg, hippocampus and prefrontal cortex) involved
in neurocognition
76,77: Chronically elevated cortisol
desensitizes CNS glucocorticoid receptors,
78 altering glu-
tamatergic N-methyl-D-aspartate receptor activity
79 with
Figure 2. Proposed model of how a biological stress response in late-life anxiety produces cognitive impairment, and how mindfulness-based treatment
for late-life anxiety disorders may reverse this cognitive impairment. CRH, corticotropin-releasing hormone; ACTH: adrenocorticotropin hor-
mone
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structures.
69,80,81
Some of these changes appear to be reversible.
69,82 For
example, memory and hippocampal volumes in depres-
sion and anxiety disorders appear to be dynamic,
increasing with successful treatment,
75,83,84 including in the
elderly.
85 Thus, treatments for late-life mental disorders
that reduce HPA axis hyperactivity ought to improve
cognition. In a series of articles examining cortisol in
late-life GAD, we found support for this hypothesis. We
found that older adults with GAD had HPA axis hyper-
activity, with 40% to 60% higher cortisol levels than
comparisons.
61,86We also found a neuroendocrine effect
of treatment: subjects who received escitalopram had a
12% to 15% reduction in peak and total cortisol with
escitalopram (vs no change with placebo).
86 The neu-
roendocrine effect was correlated with reduced anxiety.
This indicated that HPA dysfunction in late-life anxiety
is modifiable with treatment. Finally, we found that cor-
tisol changes during treatment predicted memory
improvement; that is, we found significant improvements
in immediate and delayed memory in escitalopram-
treated subjects whose cortisol levels decreased.
87 In all,
this research suggests that reducing the biological stress
response might be one treatment target for cognitive
improvement in late-life anxiety disorders, which we dis-
cuss further later in this review. 
A chronically elevated stress response seen in late-life
anxiety may cause cognitive decline by other mecha-
nisms. Some studies have found increases in β-amyloid-
42 peptide (Aβ42) production and tau hyperphospho-
rylation attributable to excessive HPA activation
(mediated via corticotropin releasing factor-1 [CRF1]),
showing a link between chronic stress in aging, increased
CRF production, and the putative pathogenic steps in
Alzheimer’s disease
88-90; this provides other putative
mechanisms for cognitive decline in the context of
chronic anxiety, mediated by excessive or altered HPA
axis activation. Late-life depression is associated with
immune activation, so this relationship might also be
true in late-life anxiety.
91,92,93 Cardiovascular disease is the
main cause of premature mortality in mental illness,
94
and some research has elucidated mechanisms between
anxiety in elderly and cardivascular disease—insulin
resistance, endothelial reactivity, and altered autonomic
function.
95 Research in chronic psychosocial stress and
reduced telomere length
96,97 has given rise to the hypoth-
esis that chronic affective disorders lead to telomere
shrinking
98; hence chronic anxiety may be accelerating
aging at a cellular level. Finally, altering serotonin func-
tion in an aging model appears to affect stress responsi-
tivity as well as longevity and age-related neurodegen-
eration.
99
An apt summary of these myriad findings would be that
stress research and aging research are intersecting: accel-
erated aging and stress hyperreactivity (as seen in anxiety
disorders) are overlapping concepts. Thus, for late-life
anxiety disorders, agents that affect aging pathways (such
as rapamycin or calorie restriction mimetics) may be
among the novel treatments that benefit health and cog-
nition. Unfortunately, despite the wealth of research in
the stress, immunology, and aging fields that could be
applied to elucidate these connections, no longitudinal
research, to our knowledge, has been done or is underway
to elucidate the long-term consequences of chronic patho-
logical anxiety in late life, their mechanisms, and/or novel
treatments to reverse this “accelerated aging” process. 
Comorbidity of anxiety with 
depression in the elderly
Depressed individuals at all ages, including older adults,
commonly have comorbid anxiety symptoms or disor-
ders. Longitudinally, anxiety symptoms appear to lead to
depressive symptoms, more likely than is the case vice
versa.
100Anxiety disorders could therefore be a risk fac-
tor for late-life depression as well as a predictor of per-
sistence and relapse, as in young adults.
14,101,102-106 Some
research disputes this assertion.
107 On the whole, though,
studies support the conceptualization of anxious depres-
sion as a severe, treatment-relevant subtype of depres-
sion throughout the lifespan. It remains unknown
whether anxious depression reflects diagnostic or dimen-
sional phenotypic overlap, a common neurobiological,
behavioral, and/or psychological underpinning, or some
additional heterogeneity. Anxious depression might be
particularly relevant in older adults, in whom it predicts
more cognitive decline
44 and greater suicide risk
108 than
nonanxious depression.
Treatment
Pharmacological treatments for anxiety disorders do not
always have the same benefits or risks across the lifes-
pan. Additionally, in the case of psychotherapy, treat-
ments typically need to be adapted for older adults.
30,109
385
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anxiety disorders, discusses new directions in treatment
development for older adults, and then provides a set of
management guidelines for clinicians.
Psychotherapy
Cognitive behavioral therapy (CBT) is the mainstay for
anxiety disorder treatment. In younger adults, it is a
treatment of choice, particularly when exposure-based,
for most anxiety disorders (although it is by no means
the only effective approach in these cases). It remains
unclear whether CBT is superior to other psychotherapy
approaches in late-life anxiety disorders; however, this
is presently the dominant and most widely available for-
mal psychotherapy for anxiety disorders. CBT might be
particularly effective for anxiety disorders in cognitively
intact, motivated older adults who are able to learn new
skills in CBT and use them effectively.
110
CBT for late-life anxiety typically involves psychoedu-
cation, relaxation, cognitive therapy, problem-solving
skills training, exposure and habituation to anxiogenic
situations, and sleep hygiene when necessary for insom-
nia, similar to treatment in younger adults.
111 In older
adults, the most effective ingredient of CBT may be
relaxation training, which is fairly simple for providers.
112
With respect to long-term management of this chronic
disorder, naturalistic follow-up studies of older GAD
patients treated with CBT have demonstrated mainte-
nance of gains for up to 1 year following discontinuation
of treatment.
113
There are some limitations to CBT for older adults with
anxiety disorders. First, both a meta-analysis and a small
direct randomized comparison of pharmacotherapy and
psychotherapy found medications to be more effective
than CBT in the acute phase of treatment.
114,115
Additionally, although CBT has been shown to be effec-
tive in the primary care setting,
116 the lack of CBT ther-
apists with experience in late-life anxiety is a barrier to
widespread implementation.
Adaptations for older adults include a slower pace with
increased repetition, less abstract cognitive restructur-
ing techniques and correspondingly more focus on
behavioral change, more focus on health concerns, and
engagement of the family in the treatment. In addition
to in-session discussion and a written summary of mate-
rial, it is useful to audiotape sessions for participants to
increase the learning of new material. Another possible
adaptation is the integration of religion into CBT, par-
ticularly in older adults who often have more of a spiri-
tual view of their lives.
117
Modular treatment reflects a novel approach in psy-
chotherapy research in which the patient’s presenting
problems or symptoms are used to choose the specific
components of treatment.
118,119 This patient-centered
process appears to increase engagement and reduce
attrition
120,121 and may be more cost-effective. 
Some other psychotherapy treatment modalities are
worth mentioning. First, bibliotherapy, or guided self-
help, has long been a low-cost and widely available alter-
native (or addition) to a full-scale psychotherapy proto-
col.
122 Such self-help guides exist using CBT, Acceptance
and Commitment Therapy, or mindfulness models; they
can be used as a first step in, or complement to, formal
psychotherapy (or pharmacotherapy) approaches. A
recent study of late-life anxiety and depression preven-
tion used a stepped-care approach, in which the first
intervention was bibliotherapy, was effective at pre-
venting anxiety and depressive episodes.
29 Many self-
help workbooks exist for anxiety disorders, though none
to our knowledge are focused on older adults. There is
increasing indication that many patients are using the
Internet as a guide for treatment, although it is unknown
to what extent this is the case for older adults. As such,
Internet-based self-help may be another increasingly-
available, low-cost psychotherapy option that is little-
studied in this age group. Organizations such as the
Anxiety Disorders Association of America and the
Geriatric Mental Health Foundation offer psychoedu-
cational help for late-life anxiety disorders on-line.
Novel treatment directions for psychotherapy in 
late-life anxiety disorders
Worry and rumination are important driving forces in
late-life mental disorders.
123-125 Poorer executive function,
which is associated with aging, is associated with
decreased ability to inhibit rumination and worry.
126-130
Recent studies demonstrate that putative neuroimaging
markers for rumination
131,132 increase with aging.
25,133-136
Worry and rumination are associated with HPA axis
hyperactivity in late-life mental disorders; for example,
we found that excessive worry robustly predicted corti-
sol levels in late-life generalized anxiety disorder (GAD)
patients,
61 and that reduction of worry predicted cortisol
reduction during treatment.
86
386
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These data generate the hypothesis that interventions
that reduce pathological worry and rumination will
reduce HPA axis hyperactivity and thereby improve cog-
nition as well as clinical symptoms in late-life anxiety dis-
orders and depression. Unfortunately, standard treat-
ments for these disorders in older adults are of modest
efficacy for pathological worry and rumination.
116,137,138
Thus, new and effective psychosocial interventions are
needed.
139
Hyperactive stress response due to pathological worry
and rumination may be an ideal target for mindfulness
meditation. Mindfulness meditation emphasizes focused,
nonjudgmental awareness of present moment experi-
ences as an alternative to dwelling on the past (eg, rumi-
nating)
140 or future (eg, worrying).
141 One mindfulness-
based intervention, Mindfulness-Based Stress Reduction
(MBSR) has been shown to improve anxiety
142-144 and
other psychological outcomes in clinical trials. It is
already practiced in every major city in the US and in
over 250 clinics, hospitals, and HMOs in the US and
abroad.
145 Mindfulness meditation programs have seen
an explosion of interest and acceptability among older
adults.
146-150 MBSR appears to increase mindfulness,
151 a
state of present-centeredness that is the converse of
worry about the future and rumination about the past.
152
Accordingly, several studies have demonstrated a rumi-
nation- and worry-reducing effect of MBSR.
140,153,154
Accordingly, multiple studies of MBSR have demon-
strated potent cortisol-lowering effects, suggesting that
increasing mindfulness reduces excessive HPA axis
responses.
155,156 Thus, MBSR appears promising, concep-
tually and empirically, as a treatment for the factors that
underlie neurocognitive impairment and clinical out-
comes in late-life anxiety disorders, as shown in the
model in Figure 2b. 
Pharmacotherapy
Benzodiazepines are still commonly used for geriatric
anxiety.
157 However, the risk:benefit ratio of these med-
ications is poorer in older adults than in younger adults.
In older adults, these medications are associated with
falls,
158 disability,
159 and cognitive impairment and
decline.
160 The risks occur at doses lower than the usual
efficacious dose of these medications for anxiety disor-
ders. Thus, these medications do not just have a tight
therapeutic index, they have a reverse index (dose for
harms lower than dose for benefits) with increasing
aging. For this reason, they should be considered short-
term adjuncts to treatment, with long-term use only as a
last resort. 
Two small RCTs
115,161 provided important feasibility data
and preliminary evidence of the efficacy of selective
serotonin reuptake inhibitors (SSRIs) in the acute treat-
ment of older adults with anxiety disorders, predomi-
nantly GAD. As a result, one of us (EJL) led the first
and, to our knowledge, only full-scale RCT of an SSRI
for acute treatment of late-life anxiety disorders.
137 We
randomized 177 older adults with GAD to the SSRI esc-
italopram, flexibly dosed at 10 to 20 mg daily, or placebo
for 12 weeks. Escitalopram was shown to be efficacious,
with greater cumulative response (69% vs 51%, P=0.03)
and greater improvements in worry severity and role
function. The effect size for most clinical outcome mea-
sures was in the low-medium range. A reasonable con-
clusion from this full-scale study, together with the pilot
studies, is that SSRIs are efficacious but show the same
disappointing effect sizes as in studies of young adults
(or older adults with depression).
162
There are caveats to this conclusion: first, a single rela-
tively small full-scale study is unlikely to be adequate for
clarifying the extent of benefits for any treatment
(although, as mentioned previously, we are unaware of
any current efforts for another); perhaps the effect size
of SSRIs is higher, or lower, than we found in that study.
Second, all of these studies suffer the limitations of the
measures used in anxiety trials, such as the Hamilton
Anxiety Scale
163 and Penn State Worry Questionnaire.
Finally, clinical symptomatology is not the only impor-
tant outcome of late-life anxiety disorder treatment. In
fact, it may be the least important, as patients are typi-
cally more concerned about their quality of life and their
systemic and (in particular) cognitive health, such as
memory decline. In that study, we measured quality of
life (which improved, albeit modestly, more with esci-
talopram than placebo) and also cognitive health, using
neuropsychological testing as a proxy.
164 We found that
improvement in late-life GAD was associated with sig-
nificant improvements in a variety of cognitive mea-
sures; however, patients randomized to escitalopram
showed greater improvement than those randomized to
placebo in only one neuropsychological testing—a sort-
ing task that is a proxy for some aspects of executive
function. Thus, although, as noted previously, in some
individuals (namely those with reduction in cortisol dur-
ing treatment) there were some cognitive improvements,
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in the aggregate the SSRI treatment was disappointing
for its acute benefits for cognitive function and quality
of life. The SSRIs may be too nonspecific and “broad-
spectrum” to hope for significant cognitive benefits in
late-life anxiety treatment.
There have been no prospective studies of serotonin
norepinephrine reuptake inhibitors (SNRIs) specifically
in late-life anxiety as there have in late-life depression.
A retrospective examination of phase 3 venlafaxine XR
data found the drug to be efficacious in adults aged 60+,
with an effect size (drug-placebo difference) and side-
effect profile similar to younger adults.
165 Similar find-
ings have been reported with duloxetine.
166
These studies in SSRIs and SNRIs have found similar
side effects in elderly persons as in younger adults, but
importantly they were not designed to determine the
recently reported potential risks of SSRIs specific to the
elderly population: gait impairment increasing risk for
falls,
167 and bone loss.
168 Other risks that are greater in
older adults are impaired clotting leading to non-GI and
GI bleeding
169 and SIADH leading to hyponatremia.
170
Such reports suggest that the risk:benefit ratio for long-
term SSRI/SNRI use is not the same as in younger
adults. These concerns have yet to be addressed in a
properly constructed longitudinal study (ie, a random-
ized controlled trial with an adequate safety evaluation).
In terms of non-SSRI/SNRI treatments, a large-scale
study with pregabalin in geriatric GAD showed effi-
cacy.
171 Pregabalin is not FDA-approved to treat anxiety
disorders; its mechanism of action for anxiety is
unknown—it binds to an auxiliary subunit voltage-gated
calcium channels and is thought to reduce the synaptic
release of several neurotransmitters. Mirtazapine is
another non-SSRI/SNRI treatment with efficacy in anx-
iety, with some evidence specifically in late-life anxiety
disorders.
172
Most geriatric anxiety pharmacotherapy research has
focused on GAD. There has been one promising study
of the SSRI citalopram in older adults with PTSD,
173 and
also evidence that the α-adrenergic antagonist prazosin
is efficacious for sleep-related concerns in PTSD,
although not for other PTSD symptoms.
174There are two
small studies in late-life panic disorder: Rampello et al
175
found superiority of escitalopram over citalopram in
time to response, and a small open-label study found
promising signals with sertraline.
176 Finally, in GAD in
the context of stroke, one analysis found efficacy of nor-
triptyline in a merged dataset of several RCTs of post-
stroke depression, in which patients with comorbid
GAD were analyzed.
177
The only published augmentation study in late-life anx-
iety disorders is a small study with risperidone.
178 While
the atypical antipsychotic was promising, there have
been concerns with atypicals in older adults, given evi-
dence of higher mortality with antipsychotics in older
patients with dementia, and metabolic effects including
weight gain, elevated lipids, and insulin resistance. It is
unclear whether the mortality risk applies to nonde-
mented older adults, but the metabolic risks certainly do. 
Finally, long-term or maintenance treatment of late-life
anxiety with medication has not been studied (although
we are currently carrying out a study of maintenance
effects of SSRI treatment in late-life GAD), and no aug-
mentation strategies can be recommended with confi-
dence. 
Combining medication and psychotherapy for late-life
anxiety disorders
The inadequacy of monotherapy is well known in mood
and anxiety disorders, and combination treatments may
be more effective.
179Antidepressants and CBT have dif-
ferent mechanisms and may be able to treat different
components of the illness.
180,181 Combination treatment in
older adults might best be carried out sequentially,
rather than simultaneously initiated, to maximize cost-
effectiveness and allow the patient and provider to focus
sequentially on different aspects of treatment, rather
than divide focus among multiple treatments and com-
ponents of illness at once.
182 The hope is that, with two
treatments targeting the different facets of the illness,
persistent residual features and relapse are less likely. 
Supporting this assertion, a recent review of meta-analy-
ses concluded that psychotherapies involving cognitive
and behavioral strategies for GAD are superior to
nondirective therapy and pill placebo, and equivalent to
pharmacotherapy in the acute phase of treatment, with
robust effects extending as far as 10 years following dis-
continuation of treatment.
183 In one study of anxious
older adults, benefits of CBT were increased at 1-year
follow-up in patients who had been treated for at least 3
months with medications prior to receiving CBT, sug-
gesting that sustained or increasing gains are possible for
older adults receiving CBT for anxiety following an
acute course of pharmacotherapy.
184
The strategy of sequencing medication with CBT is con-
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troversial in the anxiety disorders.
185,186 Pharmacotherapy
might interfere with the challenging of catastrophic
beliefs during psychotherapy, individuals treated with
medications may be less motivated to engage in psy-
chotherapy, and psychotherapy in the context of med-
ications may result in state-dependent learning that does
not persist after the medication is discontinued.
187,188
Because of this, we are currently testing the strategy of
sequenced medication and CBT within a controlled
study design.
Future directions in treatment development: 
new targets and one large barrier
The preceding sections raise several avenues for novel
treatment development. Our findings with cortisol in
late-life GAD are summed up as such: elevated cortisol
is associated with GAD, is reducible with treatment, and
when reduced during treatment is associated with neu-
ropsychological improvements (in memory). Thus, the
biological stress response (for which cortisol is a media-
tor or proxy) may be a prime target for novel pharma-
cological (ie, cortisol-blocking) or behavioral (ie, worry-
reducing) strategies, with the effect of improving not
only clinical but also cognitive functioning. Conversely,
researchers also need to consider how to improve anxi-
ety in cognitively-impaired older adults, particularly
those whose impairment has evolved into dementia,
realizing that for many if not most, such a level of cog-
nitive impairment is not likely to improve with any treat-
ment (anxiety or otherwise).
The biological stress response may also be a target in
improving systemic health in late-life anxiety disorders.
The dramatic health impact not only of late-life anxiety
disorders but also in other chronic stress models, such as
is seen in spousal caregivers of AD patients, suggests that
more mechanistic work is needed to delineate the path-
ways from psychosocial stress as seen in chronic anxi-
ety/worry to adverse health. Fortunately, new tools (such
as genome-wide expression or proteomic analysis, or
novel imaging techniques to measure CNS or peripheral
inflammation) should make this research more feasible. 
Less mechanistic than a specific biological pathway but
at least as important is the concept of function as a tar-
get. Anxiety disorders are disabling, just as is depression
in older adults. For example, fear of falling is in some
patients a highly disabling condition akin to severe ago-
raphobia. New methods are needed to measure and
improve function in older adults that is relevant to anx-
iety disorders.
In terms of one major barrier to progress in late-life anx-
iety research, we turn again to the issue of measurement.
Progress in measurement techniques is a prerequisite for
scientific advances, yet in the area of late-life anxiety dis-
orders our measurements are antiquated and demon-
strably inadequate, hampering research progress. This is
true across the lifespan but may be particularly pressing
in geriatrics. We have previously reviewed this issue of
inadequate measurement in some depth
30 but will sum-
marize key concerns here.
Variability in diagnostic criteria and tools leads to dis-
crepant epidemiological findings: as reviewed in-depth
elsewhere,
2 epidemiologic studies have found dramati-
cally different prevalence and incidence estimates.
Numerous issues hamper our ability to accurately diag-
nose or characterize anxiety disorders in older adults,
189
and a recent review has suggested ways to improve diag-
nosis so that DSM-5 might be more sensitive to late-life
anxiety disorders.
4 Additionally, it has been suggested
that the problems described above reflect the limitation
of using diagnostic categories, and the solution is to
move towards dimensional assessments of illness.
190Yet,
the challenge of measuring geriatric anxiety goes beyond
diagnosis. The problems of symptom assessment in geri-
atric mental health are complex and not necessarily ones
that can be resolved with existing or adapted sympto-
matic assessments. Instead, technological advances could
develop novel ways of monitoring the severity and phe-
nomenology of anxiety and its response to treatment.
These advances include: (i) improved subjective symp-
tom measurement via electronic daily or momentary
assessment; (ii) improved measurement of function via
actigraphy and other assessments; and (iii) assessment
of the physiological and cognitive benefits of treatment
via biomarkers. These are described in more detail
below.
Electronic assessment of symptoms
Anxiety symptomatology has traditionally been assessed
using retrospective self-report.
191-197 Such measures
require participants to recall, average, and summarize
their experiences and are subject to bias and error; for
example, disproportionate weight may be given to highly
significant past instances relative to current or ongoing
events.
198-207 Current state assessment seems critical for
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experience. 
Ecological momentary assessment (EMA) involves
repeated measurement of momentary experiences nat-
uralistically and in real time.
208 It has been used to assess
stress, behavior, and other physical and mental health-
related constructs.
209-214The key features of EMA are that
it samples: (i) present moment experience (ie, as
opposed to recalled, averaged, or summarized experi-
ence); (ii) in its natural context (ie, outside of a labora-
tory); (iii) repeatedly over time (often up to eight times
per day). The availability of electronic means of data
capture, such as mobile devices, has greatly facilitated
the use of EMA. For example, participants can be
prompted at random intervals by a device to respond to
a brief series of questions about the present moment;
responses are input immediately by the participants, with
data transmitted wirelessly to the investigator.
215-217
Given its capability of evaluating momentary experi-
ence, EMA appears well suited to examine anxiety
symptomatology. EMA avoids reporting biases such as
recency and severity effects, “telescoping,” and difficul-
ties with estimation. These biases are particularly rele-
vant for elderly. These types of assessments can also cap-
ture diurnal variations in symptoms. Yet even these
assessments require a fair degree of insight by the user;
we may need assessments of anxiety severity that do not
require subjective assessment by the patient. 
Novel measures
Novel measures may also improve our measurement of
disability (or behavior change) stemming from anxiety.
Actigraphy findings have been used to measure depres-
sion severity and treatment response.
218-220Actigraphy is
particularly useful in examining sleep, activity, and cir-
cadian rhythm, so these patterns could potentially pro-
vide an objective measure of response that could com-
plement self-report. A similar use of objective
assessment technology might be the use of global posi-
tioning (GPS/GIS) to gather extensive data on activity
and therefore on function. 
Biomarkers
Finally, measurement of biomarkers may be able to char-
acterize one aspect of anxiety disorders most notable in
older adults: their deleterious effects on cognitive and
physiological health. Neuropsychological testing has
long existed (though rarely examined in treatments of
anxiety disorders). Newer biomarkers could evaluate
treatment response in older adults in whom anxiety is
most likely to have long-term adverse health or cogni-
tive consequences. These may include HPA axis func-
tioning through cortisol sampling, or genome-wide
expression analysis, a powerful high-throughput tech-
nology that provides a systems approach for examining
complex clinical disease in terms of dynamic changes in
gene expression.
221 Genome-wide expression analysis
assays the current activity level of all transcripts known
in humans. Thus, for example, a researcher can deter-
mine whether stress results in higher or lower levels of
RNA transcripts in peripheral immunological cells.
222
Such data, combined with bioinformatic techniques,
allow researchers to infer the functioning of all of the
intracellular pathways at a given point in time (ie, at
baseline and then after a treatment), as well as their
interactions.
223,224 Additionally, as we previously noted,
chronic stress hyperactivity (as seen in anxiety disorders)
may cause accelerated aging; thus, telomere length mea-
surement, during the course of a treatment study, might
provide a precise and quantitative estimate of benefits
of treatment for health and cognition of older adults.
Finally, novel neuroimaging markers might include neu-
rogenesis, functional connectivity, and peripheral and
central inflammation. In all, recent advances in technol-
ogy in studies of anxiety could increase our precision for
measurement, a need most pressing in geriatrics.
What we do know: 
eight rules for managing anxiety disorders
from a lifespan perspective
In this last section, we provide a blueprint for managing
older (and equally so, younger) adults with anxiety dis-
orders, based on empirical findings and our own clinical
experience. 
1. Assessment should measure severity and provide
objective criteria for assessing response, and should
assess comorbidity, prior treatment, cognitive status, and
need for a medical workup
Assessment of anxiety is often overlooked by mental
health providers. A helpful introduction to the topic is to
ask about stress; eg, “older adults often deal with stress;
State of the art
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describe symptoms suggestive of anxiety or worry can
then be further queried. Use nondirective questioning
to determine the severity of anxiety symptoms, by: (i)
level of distress (asking how much the anxiety symptoms
bother the patient, what strategies they are trying in
order to control or avoid it, and what somatic symptoms
they are having); (ii) how much of their time it takes; and
(iii) avoidance. Avoidance is a key component of all anx-
iety disorders yet often is not recognized. For example,
older adults may rationalize changes in behavior pat-
terns to perceived poor health or environmental limi-
tations. Inquire about behavioral changes including
activities given up or, conversely, intrusive overinvolve-
ment with family members. Talk to the family for cor-
roboration. 
We are often asked about differentiating anxiety from
depression. In our experience, some patients (and some
neurobiologists!) fail to appreciate the importance we
place on this diagnostic distinction. Clinically, the clini-
cian will often have to deal with anxiety as well as
depression in a patient. 
The medical differentiation of late-onset anxiety is long
but should chiefly consider: (i) depression; (ii) cognitive
impairment (dementia, delirium); (iii) anxiety-inducing
medications (or recent discontinuation or inconsistent
use of sedatives); and (iv) common and rare medical
conditions that could masquerade as an anxiety disor-
der. Regarding the latter, consider thyroid disease, B12
deficiency, hypoxia, ischemia, or metabolic changes (eg,
hypercalcemia or hypoglycemia).
2. Think twice about a benzodiazepine prescription
As previously noted, benzodiazepines, like any sedatives,
have a poorer risk:benefit ratio in elderly persons than
in young adults. Therefore, long-term use of benzodi-
azepines appears unfavorable in this age group. Patients
should be warned about the potential risks associated
with these medications.
Benzodiazepines provide a fast anxiolytic action, so a
common recommendation is to use these medications at
low dose as a short-term adjunct, in which case they may
provide some early relief and improve adherence to the
treatment regimen. Even this adjunctive use of benzo-
diazepines is typically unnecessary and can reinforce an
inappropriate message to patients that anxiety must be
immediately relieved, which is akin to an avoidance
response. 
3. Psychoeducation about anxiety and treatment, includ-
ing potential health benefits
Psychoeducation may be the most important manage-
ment step. Providers should inform patients that they
have a treatable condition and should address stigma,
misinformation, and other common and surmountable
barriers to treatment. Emphasize the importance of
treating anxiety for improving quality of life, health, and
brain health. Include the family in these discussions. 
4. First-line treatment according to patient’s preference,
provider preference and competence, and treatment
availability 
First-line options include one or more of the following:
SSRI, SNRI, relaxation training, and CBT. Bibliotherapy
can and should be recommended alongside any of these
options. Often these options will need to be started along
with, or after, discontinuation of harmful or inappropri-
ate confusogenic medications such as sedatives, anti-
cholinergics, and antihistaminergics.
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Childhood/adolescence Adulthood Old age
Key presenting  Irritability, poor sleep,  Fatigue, poor sleep, irritability, Poor concentration or memory,
complaints somatic symptoms somatic symptoms fatigue, poor sleep, somatic symptoms
Contexts School Work, social settings Activities of daily living, health care settings
Burden School refusal, burden on parents Occupational disability, interpersonal  Excess health care utilization, caregiver
dysfunction, excess health care  burden, cognitive decline, cardiovascular and
utilization other age-related disease, excess disability, 
premature mortality
Main comorbidities Depression Depression, substance abuse Depression, dementia
Table II. Features of anxiety disorders across the lifespan.
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of treatment or dose change, to encourage adherence
and monitor treatment response
Most anxious adults will receive a pharmacological trial
as first-line treatment. Older adults vary from young
adults in terms of increased comorbid medical condi-
tions, pharmacokinetic changes, frailty, and drug inter-
actions. Yet, anxious older adults’ reports that they are
sensitive or intolerant of antidepressant medications
appears to result less from actual side effects than from
their anticipatory concern, vigilance towards interocep-
tive stimuli, and tendency to catastrophize about any
interoceptive sensations they detect. 
Overcoming such fears related to the medication’s
potentially negative effects is not an easy task. This task
is made more difficult by the standard list of potential
side effects with any medication, many of which sound
frightening or are symptoms that the patient already has
(eg, fatigue, insomnia). To combat these fears proactively,
describe how such antidepressant medications have
established efficacy and high tolerability. Also, a health
care provider should describe their experience in pre-
scribing this medication and state that, while side effects
are possible, no particular side effect is inevitable: most
patients taking the medication will either have no side
effects or will have brief, self-limited side effects which
subside in a few weeks. Emphasize that the medication
is unlikely to be incapacitating. When patients mention
that “I already have that symptom,” they are not more
likely to have that as a side effect as a result; in contrast,
physical symptoms tend to decrease with pharmacolog-
ical treatment.
225
Family involvement can help with adherence.
Nevertheless, most patients will have additional concerns
after the medication is prescribed, especially before and
just after they take the first dose. Address this in several
ways, stating to patients/families that it is natural to have
questions, and encouraging them to call, providing 24-
hour contact information (typically patients do not, but
benefit from the knowledge that they can). Ideally, as in
clinical trials, we would provide weekly visits, or bi-
weekly visits with interim telephone contacts, for the first
month of treatment and the month subsequent to a dose
increase, since this is when patients are most likely to
develop concerns about side effects.
Follow-up includes interviewing patients closely for any
concerns about perceived side effects. Patients often
seem to perceive as side effects symptoms that predate
the start of medication and are clearly a component of
the disorder. In anxiety, adherence issues stem from vig-
ilance to perceived side effects and subsequent cata-
strophizing. If such an issue is noted, an immediate con-
tact will reassure the patient that they are being
monitored closely by experts and that the medication is
not causing some sort of severe or worsening problem.
This brief but timely intervention reduces premature dis-
continuation of pharmacotherapy.
Geriatric anxiety disorder patients usually get better, but
given the fluctuating nature of the disorders and the
issues with insight, they often do not realize they are
improving. Repeated assessment of frequency and sever-
ity of anxiety is important not just for assessing success
of treatment but also demonstrating improvement to the
patient.
6. With medications, start low, go slow, but go—as
aggressively as required to treat symptoms to remission
After psychoeducation and clean-up of inappropriate
medications, the proximal goal of acute care is to get the
patient a treatment trial of sufficient intensity and dura-
State of the art
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Diagnostic
-Older adults appear to have lower overall prevalence of anxiety 
disorders, compared with younger adults.
-It remains unclear whether these lower rates reflect a true decline 
in anxiety, changes in presentation of anxiety, or difficulties with 
detecting and diagnosing anxiety disorders, with aging.
-Anxiety disorders remain common, chronic, and highly impairing 
disorders in old age.
Presentation
-A presentation of worry predominates more so than panic or 
phobias in old age, which is a reversal of earlier in the lifespan.
-The key impairments of anxiety disorders vary across the lifespan 
(chiefly school in young age, work in adulthood, and health care 
utilization and caregiver burden in old age).
Treatment
-Sedative anxiolytics, including benzodiazepines and 
antihistamines, have a poorer risk:benefit ratio in older adults.
-Other pharmacological strategies appear equally effective 
(or ineffective) in older and younger adults.
-Psychotherapy appears less effective in older adults than younger 
adults, possibly due to cognitive impairment imposed by the 
anxiety disorder in this age group.
Table III. Key points from a lifespan view of anxiety disorders.
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tion, often at high doses that do not vary across the lifes-
pan in the case of SSRIs/SNRIs.
7. Consider augmentation treatment and refer to experts
if necessary
Monotherapy is usually inadequate, and if a good trial is
only partially effective, add another. Providers should
not “run out of options” but then should refer a patient
to someone with additional expertise in (eg, a geriatric
psychiatrist or a psychotherapist skilled at treating anx-
iety disorders). 
8. Provide maintenance treatment; evaluate the need for
such if treatment is discontinued
Since anxiety is chronic, treatment will usually need to
be long-term, ie, maintenance medication and/or booster
psychotherapy sessions. As the patient has already over-
come any fears or initial side effects, maintenance phar-
macotherapy requires less frequent oversight though
continued monitoring of clinical changes, side effects,
and changes in coprescribed medications is necessary.
If a patient chooses to taper off a medication, they
should be informed that they may need to resume treat-
ment in the event of relapse. A taper should be very
gradual (ie, over several weeks) to avoid rebound anxi-
ety symptoms. Management does not have an end point,
even when the patient is no longer receiving active phar-
macotherapy. In the case of psychotherapy benefits,
booster sessions provide important reminders to con-
tinue to use effective new coping skills.
Summary
Anxiety disorders are neurodevelopmental disorders,
and as neurodevelopment continues and changes
throughout the lifespan, even into old age, there are new,
unique issues with anxiety disorder and presentation at
each point in aging. Just as childhood offers unique per-
spectives such as the need to target parental influence
226
and the possibility for prevention, in older adults there
are new presentations (such as FOF) and new effects of
anxiety (on brain and physiological health). 
There have been many strides in our understanding of
anxiety disorders across the lifespan, but also many gaps
in our knowledge remain. The field has adequately clar-
ified the benefits of treatments developed for young
adults, as equally efficacious in older adults in the case
of pharmacotherapy, or in the case of cognitive-behav-
ioral therapy, needing adaptation in order to be effica-
cious. What is lacking are new treatments for older
adults and the understanding of the mechanisms for
onset and maintenance of anxiety disorders and how
they exert such deleterious effects on the brain and
physiologic health of older adults. 
New treatments, both behavioral and somatic, need to
be developed and tested across the lifespan. In older
adults, treatment development ought to consider the
barriers posed by cognitive impairment and even
develop treatments that target cognition as well as clin-
ical symptoms. Research needs to consider and address
the gaps raised in this review, most fundamentally our
limitations in the diagnosis and measurement of anxiety
disorders in older adults. The great public health impor-
tance of this research is highlighted by the graying of the
world population, the high human and economic cost of
anxiety disorders in all age groups, and the potential for
existing and new treatments to reduce much of this bur-
den. ❏
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Una visión de los trastornos ansiosos a lo
largo de la vida
Los cambios en el neurodesarrollo durante el curso
de la vida, desde la niñez pasando por la adultez y
hasta la vejez, tienen importantes repercusiones
para la instalación, presentación, curso y trata-
miento de los trastornos ansiosos. Este artículo pre-
senta datos acerca de los trastornos ansiosos en la
forma cómo ellos aparecen en los adultos mayores
en comparación con los más jóvenes. Este artículo
se centra en los cambios relacionados con la edad
en la epidemiología, presentación y tratamiento de
los trastornos ansiosos. Además, este articulo des-
cribe algunas de las brechas y limitaciones en nues-
tra comprensión del trastorno ansioso y sugiere
directrices de la investigación que puedan aclarar
los mecanismos de aquellos cuadros que se desa-
rrollan más tardíamente en la vida. Finalmente se
describe el manejo óptimo para los clínicos de los
trastornos ansiosos a lo largo de la vida en “ocho
pasos simples”.  
Une perspective sur la vie entière des
troubles anxieux
Les modifications neurodéveloppementales surve-
nant tout au long de la vie, de l’enfance à l’âge
adulte jusqu’à la vieillesse, ont des implications
importantes sur la survenue, le cours et le traite-
ment des troubles anxieux. Cet article présente des
données sur les troubles anxieux tels qu’ils appa-
raissent chez les adultes plus âgés, comparés à ceux
moins avancés en âge. Nous nous intéressons ici aux
modifications liées au vieillissement dans l’épidé-
miologie, la présentation et le traitement des
troubles anxieux. Cet article décrit aussi les lacunes
et les limites de notre compréhension et suggère
des directions de recherche pouvant élucider les
mécanismes du développement du trouble anxieux
plus tard dans la vie. Enfin, nous décrivons la prise
en charge optimale des troubles anxieux au cours
de la vie, en « huit étapes simples » pour le méde-
cin.
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